Therefore, developing therapeutic tumour vaccines, especially through combination of the adaptive immune response of CD8+ T cells and innate immune response of NK cells to exert targeted antitumour effects is a promising strategy [5, 6]. This evidence concerns the gene CD8A and neoplasm.